The Latest

NOW AVAILABLE: For the Lung Cancer Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for 2016.

Of the large number of brands analyzed for the lung cancer market, Merck’s Keytruda produced the highest percentage of the promotional volume during 2016, launching the “KEY+YOU” support program, and announcing a new expanded indication for Keytruda. Bristol-Myers Squibb promoted Opdivo’s “240 mg flat dose” for NSCLC, RCC, and Melanoma indications. Medimmune circulated unbranded durvalumab promotions noting that “PD-L1 pathway inhibition offers a new foundation for immunotherapy combination research”. Testing for genetic mutations at disease progression remained a priority topic with FDA-approved, companion diagnostic tests for Tagrisso and Tarceva. Multiple brands launched new campaign themes, including Abraxane, Alecensa, Iressa, Keytruda, Opdivo, Portrazza, Tagrisso, and Xalkori. Overall, materials mostly targeted healthcare professionals and support messages were prioritized. Additional insights into marketing strategies and channel utilization are available with a subscription.

2016-Lung-Cancer-

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the Biologics for Psoriasis Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for 2016.

During 2016 a total of 363 new pieces were observed in circulation within the competitive Biologics for Psoriasis market. Overall, Celgene’s Otezla was the promotional market leader advertising new GOtezla mobile app, and the introduction of the “Show More of You!” initiative to raise psoriasis awareness. Janssen focused on the “Stelara Standard”, which encompassed the product’s, efficacy, safety, dosing, and formulary coverage. Eli Lilly circulated the first branded promotions for Taltz with messages pertaining to its recent approval and availability, and the launch of the “Touching Moments” DTC campaign. Toward year end 2016, Amgen launched digital campaigns announcing the approval of Enbrel for pediatric psoriasis patients. AbbVie’s Humira encouraged patients to view testimonials as part of the new Humira Moments promotion and invited them to join the new “SPEAK Network” to share their treatment story. Novartis announced that Cosentyx was granted the 2016 Prix Galien Award for Best Biotechnology Product as well as new 2-year clinical results at ADD 2016. Pfizer circulated unbranded promotions featuring the Psoriasis PACT website. Amjevita from Amgen, Erelzi from Sandoz, and Inflectra from Pfizer were all FDA approved biosimilars. Additional insights into marketing strategies and channel utilization are available with a subscription.

2016-Biologics-for-Psoriasi

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

 

NOW AVAILABLE: For the International RA Market – A SnapShot analysis of promotional messaging and DTC initiatives for Year 2016.

Overall, the RA market produced 406 pieces during 2016. Humira distributed the highest number of items, capturing 14% of the promotional volume; however, Orencia and RoActemra/Actemra also contributed each with 13% of the materials. This increase in pieces during 2016 was due to the entry of the biosimilar Benepali/Brenzys in the European and Canadian markets as an equivalent and more economic option for RA. In addition, the announcement of Kevzara’s (sarilumab) approval in Canada and Xeljanz’s positive opinion by the EMA in Europe was an incentive for established brand drugs to increase their promotional efforts. On the other hand, discount agreements and patient support played an important role as well as persistency as a new indicator of efficacy. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

Year-End-2016-RA

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the European Psoriasis Market – A SnapShot analysis of promotional messaging and DTC initiatives for Year 2016.

The Psoriasis market generated 235 pieces during 2016. Humira replaced Stelara and Enbrel as the promotional leader, focusing on the patient with its new, enhanced presentation and the AbbVie Care patient support program, while Benepali and Taltz debuted as new therapy options. Brand drugs emphasized persistency and drug survival as indicators of efficacy and safety, and biosimilars highlighted comparability to biologics and cost-savings. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

Year-End-2016-PsO

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the European PsA Market – A SnapShot analysis of promotional messaging and DTC initiatives for Year 2016.

Overall, the psoriatic arthritis market generated 323 pieces during 2016. Enbrel initiated the year as the promotions leader for Q1, but it was surpassed by Humira for the rest of 2016. Cost savings through discount agreements with health statutory funds, patient support, and persistency as a new indicator of efficacy were the main promotional elements for the European PsA market. In addition, patient convenience played an important role with the introduction of Remicade’s new infusion service and Humira’s novel 40 mg/mL presentation. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

Year-End-2016-PsA

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the European PCSK9 Inhibitors Market – A SnapShot analysis of promotional messaging and DTC initiatives for Year 2016.

Overall, Praluent circulated more pieces in 2016; however, Repatha started taking over on promotional volume during Q3. Both brands emphasized efficacy and safety supported by several clinical studies compared to placebo and highlighted the importance of PCSK9 inhibitors in CV risk patients. In addition, familiar campaigns were gradually introduced in different European countries such as the “Virtual Screen” campaign in Spain or the “Arrow” theme in France. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

Year-End-2016-PCSK9

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the European NSCLS Market – A SnapShot analysis of promotional messaging and DTC initiatives for Year 2016.

Nivolumab BMS/Opdivo dominated the NSCLC promotional volume in Europe for most of the year, except for Q3, when Iressa was on par with Opdivo. Keytruda and Portrazza were introduced as new options to treat lung cancer, while Nivolumab BMS transitioned to its new brand name. Two campaign themes also debuted this year, the “Seasons” theme for Vargatef and the “Mosaic Lungs” imagery for Portrazza. In addition, Iressa presented an non-invasive blood test to detect ctDNA in NSCLC EGFR+ patients. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

Year-End-2016-NCSLC

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the Canadian and European Multiple Sclerosis Market – A SnapShot analysis of promotional messaging and DTC initiatives for Year 2016.

Overall, 203 pieces were produced for the Canadian and European multiple sclerosis markets in 2016, with Gilenya dominating the promotional volume in Q3 and Q4. The brands focused on the patient by providing patient programs such as (Tecfidera) or One to One (Lemtrada) to help manage the disease. Patient’s comfort was also taken into account with CSYNC, a new device to facilitate Copaxone’s dosing. In addition, the promotion of efficacy was supported by clinical studies such as ATTAIN (Plegridy) and DEFINE (Tecfidera). Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

Year-End-2016-MS

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the European Hepatitis C Market – A SnapShot analysis of promotional messaging and DTC initiatives for Year 2016.

The European Hepatitis C market distributed 236 pieces during 2016, and Exviera/Viekirax captured the highest percentage of promotional volume. Efficacy and safety in different genotypes, which were heavily supported by clinical trials, represented the most important promotional elements across brands along with patient education on Hepatitis C. This year was marked by two announcements, the introduction of Epclusa in Europe and the retirement of Incivo from the market. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

Year-End-2016-HepatitisC

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the European Biologics for GI Indications Market – A SnapShot analysis of promotional messaging and DTC initiatives for Year 2016.

The GI biologics market generated 158 pieces during 2016, and Humira produced the highest promotional volume for this market. Simponi started as a firm promotional leader at the beginning of the year, but it was replaced by Humira for the remainder of 2016. Brand drugs highlighted efficacy based on clinical studies (Entyvio – GEMINI trial) and safety, while biosimilars emphasized comparability and cost-savings. In addition, the recommendation of Stelara for the treatment of Crohn’s disease, Humira’s new enhanced presentation, and Remicade’s Infusion Service were the highlights for 2016. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

Year-End-2016-GI

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with: